These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 25855703

  • 1. Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.
    Brunetti L, Poustchi S, Cunningham D, Toscani M, Nguyen J, Lim J, Ding Y, Nahass RG.
    Ann Pharmacother; 2015 Jul; 49(7):754-60. PubMed ID: 25855703
    [Abstract] [Full Text] [Related]

  • 2. Rationale and evidence for extended infusion of piperacillin-tazobactam.
    Kaufman SE, Donnell RW, Hickey WS.
    Am J Health Syst Pharm; 2011 Aug 15; 68(16):1521-6. PubMed ID: 21817083
    [Abstract] [Full Text] [Related]

  • 3. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
    Yost RJ, Cappelletty DM, RECEIPT Study group.
    Pharmacotherapy; 2011 Aug 15; 31(8):767-75. PubMed ID: 21923603
    [Abstract] [Full Text] [Related]

  • 4. Extended-Infusion versus standard-infusion piperacillin-tazobactam for sepsis syndromes at a tertiary medical center.
    Cutro SR, Holzman R, Dubrovskaya Y, Chen XJ, Ahuja T, Scipione MR, Chen D, Papadopoulos J, Phillips MS, Mehta SA.
    Antimicrob Agents Chemother; 2014 Aug 15; 58(8):4470-5. PubMed ID: 24867975
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
    Winstead EM, Ratliff PD, Hickson RP, Mueller JE, Judd WR.
    Int J Clin Pharm; 2016 Oct 15; 38(5):1087-93. PubMed ID: 27333796
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Outcomes of an extended-infusion piperacillin-tazobactam protocol implementation in a community teaching hospital adult intensive care unit.
    Schmees PM, Bergman SJ, Strader BD, Metzke ME, Pointer S, Valenti KM.
    Am J Health Syst Pharm; 2016 Jun 01; 73(11 Suppl 3):S100-5. PubMed ID: 27208142
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
    Prabhu V, Foo J, Ahir H, Sarpong E, Merchant S.
    J Med Econ; 2017 Aug 01; 20(8):840-849. PubMed ID: 28532194
    [Abstract] [Full Text] [Related]

  • 10. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
    Bao H, Lv Y, Wang D, Xue J, Yan Z.
    Eur J Clin Microbiol Infect Dis; 2017 Mar 01; 36(3):459-466. PubMed ID: 27796647
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
    Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R.
    Pharmacotherapy; 2002 Apr 01; 22(4):471-83. PubMed ID: 11939682
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.
    Kauf TL, Prabhu VS, Medic G, Borse RH, Miller B, Gaultney J, Sen SS, Basu A.
    BMC Infect Dis; 2017 Apr 28; 17(1):314. PubMed ID: 28454524
    [Abstract] [Full Text] [Related]

  • 16. Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital.
    Xamplas RC, Itokazu GS, Glowacki RC, Grasso AE, Caquelin C, Schwartz DN.
    Am J Health Syst Pharm; 2010 Apr 15; 67(8):622-8. PubMed ID: 20360589
    [Abstract] [Full Text] [Related]

  • 17. Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections.
    Jhee SS, Gill MA, Yellin AE, Berne TV, Heseltine PN, Appleman MD.
    Clin Ther; 1995 Apr 15; 17(1):126-35. PubMed ID: 7758055
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the safety of piperacillin-tazobactam extended infusion in pediatric cystic fibrosis patients.
    Riggsbee D, Engdahl S, Pettit RS.
    Pediatr Pulmonol; 2023 Apr 15; 58(4):1092-1099. PubMed ID: 36593628
    [Abstract] [Full Text] [Related]

  • 19. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.
    Patel GW, Patel N, Lat A, Trombley K, Enbawe S, Manor K, Smith R, Lodise TP.
    Diagn Microbiol Infect Dis; 2009 Jun 15; 64(2):236-40. PubMed ID: 19500529
    [Abstract] [Full Text] [Related]

  • 20. Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
    Grau S, Lozano V, Valladares A, Cavanillas R, Xie Y, Nocea G.
    Appl Health Econ Health Policy; 2015 Aug 15; 13(4):369-79. PubMed ID: 25761545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.